Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Investment Trusts

BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)37.15
  • Today's Change0.10 / 0.27%
  • Shares traded30.70k
  • 1 Year change-12.49%
  • Beta1.1483
Data delayed at least 15 minutes, as of Sep 23 2024 13:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

  • Revenue in CHF (TTM)270.76m
  • Net income in CHF234.14m
  • Incorporated1993
  • Employees--
  • Location
    BB Biotech AGSchwertstrasse 6SCHAFFHAUSEN 8200SwitzerlandCHE
  • Phone+41 526240845
  • Fax+41 442676701
  • Websitehttps://www.bbbiotech.ch/
More ▼

Profile

Management group(s)Bellevue Asset Management, LLC
AIC sector--
ISINCH0038389992
Launch date09 Nov 1993
Share typeOrdinary Share
StructureInvestment Trust
Base currencyCHF

Objective

BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and that are generating above-average sales and profit growth. BB Biotech’s investment portfolio will usually consist of 20 to 35 biotechnology companies. This will include 5 to 8 large core positions, which together will account for up to 2/3 of the portfolio.New investments in mid-cap companies will have a weighting of between 1% and a maximum of 5% to ensure that both upside potential and R&D risks are adequately addressed.Non-listed companies should not exceed 10% of the portfolio.

Managed by

Not Disclosed

Management & contract fees

The Company pays a 1.1% all-in fee without any additional fixed or performance-based elements of compensation for the asset management company.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioArctic AB25.01m-7.38m1.04bn96.00--16.03263.6141.51-0.9972-0.99723.3910.520.2699----3,401,659.00-7.962.24-8.902.5688.2286.52-29.499.76----0.06040.00169.83-2.912,150.71-9.6911.83--
Gubra A/S26.08m-5.67m1.05bn219.00--17.19--40.35-2.91-2.9113.5129.44------936,095.90--------56.06---21.72------0.1296--2.82---1,133.04------
Genus plc757.46m8.95m1.38bn3.48k155.622.2224.681.820.11860.118610.148.300.6569--5.37--0.23573.300.27423.87----0.35894.981.42279.500.348762.72-3.036.48-76.280.2551-2.682.93
AddLife AB834.52m9.86m1.58bn2.32k165.553.8018.011.890.96830.968381.9642.190.74383.475.304,340,287.000.89375.311.378.8337.2436.891.205.790.47791.670.511331.736.6231.30-60.428.0044.43-1.89
Galapagos NV289.40m29.89m1.65bn683.0055.150.5973--5.700.47834.294.6344.160.06920.4426.01472,080.500.7149-1.480.7902-1.6588.04--10.33-14.429.87--0.0037--3.47-2.0294.42--7.04--
BB BIOTECH AG270.76m234.14m2.05bn--8.710.8513--7.584.264.264.9543.520.1024--117.67--8.862.3410.072.5297.6999.0686.4735.40----0.118217.78-57.97-37.9842.26-----8.09
MorphoSys AG175.54m-437.99m2.42bn446.00------13.79-12.48-12.595.13-8.890.09620.73575.08353,012.10-23.99-10.25-31.72-11.6185.7485.92-249.51-78.530.7747-------14.3725.53-25.60--3.11--
Data as of Sep 23 2024. Currency figures normalised to BB Biotech AG's reporting currency: Swiss Franc CHF

Institutional shareholders

6.76%Per cent of shares held by top holders
HolderShares% Held
Z�rcher Kantonalbank (Investment Management)as of 28 Jun 2024973.77k1.76%
Credit Suisse Asset Management (Schweiz) AGas of 31 Jul 2024894.93k1.62%
UBS Asset Management Switzerland AGas of 02 Jul 2024766.36k1.38%
Border to Coast Pensions Partnership Ltd.as of 31 Mar 2024224.58k0.41%
Vontobel Asset Management AGas of 30 Apr 2024218.11k0.39%
Union Bancaire Priv�e, UBP SAas of 31 Mar 2024192.72k0.35%
Pictet Asset Management SAas of 31 May 2024149.07k0.27%
BlackRock Asset Management Schweiz AGas of 04 Jul 2024111.38k0.20%
Banque Cantonale Vaudoise (Investment Management)as of 31 Mar 2024108.38k0.20%
Basler Kantonalbank (Investment Management)as of 31 Dec 2023107.35k0.19%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.